Ensaculin

From Self-sufficiency
Jump to: navigation, search
Ensaculin
240px
Systematic (IUPAC) name
7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one
Pharmacokinetic data
Biological half-life 13.7 hours
Identifiers
CAS Number 155773-59-4
ATC code none
PubChem CID 208923
Chemical data
Formula C26H32N2O5
Molar mass 452.543[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ensaculin (KA-672) is a drug from the coumarin family, which has been researched as a potential treatment for dementia. It acts on a number of receptor systems, being both a weak NMDA antagonist and a 5HT1A agonist.[1][2] Animal studies have shown promising nootropic effects,[3][4] although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic hypotension (low blood pressure).[5]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Lishko PV, Maximyuk OP, Chatterjee SS, Nöldner M, Krishtal OA. The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist. Neuroreport. 1998 Dec 21;9(18):4193-7. PMID 9926872
  2. Winter JC, Helsley SE, Rabin RA. The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component. Pharmacology, Biochemistry and Behaviour. 1998 Jul;60(3):703-7. PMID 9678654
  3. Hoerr R, Noeldner M. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Reviews. 2002 Summer;8(2):143-58. PMID 12177685
  4. Knauber J, Müller WE. Anseculin improves passive avoidance learning of aged mice. Pharmacological Research. 2003 Mar;47(3):225-33. PMID 12591018
  5. Sourgens H, Hoerr R, Biber A, Steinbrede H, Derendorf H. KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. Journal of Clinical Pharmacology. 1998 Apr;38(4):373-81. PMID 9590466